rAd-ASPP2 treatment significantly inhibited tumor growth, but treatment with rAd-ASPP2 combined with ne-EGFR was a more powerful inhibitor of transplanted tumor growth than rAd-ASPP2 treatment alone or rAd-ASPP2 combined with erlotinib (Figure 7C) because ne-EGFR extended and amplified ASPP2-induced apoptosis (Figure S5D). This evidence concerns the gene EGFR and neoplasm.